Edgewise Therapeutics, Inc.
EWTX
Peringkat dalam Saham
#3979
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing... Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
Harga Saham
$38.12
Terakhir disinkronkan: 2026-10-19
Kapitalisasi Pasar
$4.10B
Perubahan (1 hari)
2.50%
Perubahan (1 tahun)
147.69%
Negara
US
Perdagangan Edgewise Therapeutics, Inc. (EWTX)
Kategori
Healthcare
Rasio P/S untuk Edgewise Therapeutics, Inc. (EWTX)
Rasio P/S per October 2026 TTM: 0.00
Menurut laporan keuangan dan harga saham terbaru dari Edgewise Therapeutics, Inc., rasio P/S saat ini (TTM) adalah 0.00. Pada akhir 2023, rasio P/S perusahaan adalah 0.00.
Riwayat rasio P/S untuk Edgewise Therapeutics, Inc. dari 2019 hingga 2026
Rasio P/S pada akhir setiap tahun
| Tahun | Rasio P/S | Mengubah |
|---|---|---|
| 2026 (TTM) | 0.00 | 0.00% |
| 2024 | 0.00 | 0.00% |
| 2023 | 0.00 | 0.00% |
| 2022 | 0.00 | 0.00% |
| 2021 | 0.00 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
Rasio P/S untuk perusahaan sejenis atau pesaing
| Perusahaan | Rasio P/S | Perbedaan Rasio P/S | Negara |
|---|---|---|---|
| 10.02 | - |
US
|
|
| 40.55 | - |
US
|
|
| 3.96 | - |
AU
|
|
| - | - |
CH
|
|
| 10.15 | - |
NL
|
